ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±Ò¶»Ûݼ¡¢¡¢¹Ø¼ÒÆæ¡¢¡¢ÌÆÑÞÀö£©ÈÕǰ£¬£¬ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÔÚÖé½Ð³ÇÔºÇøÊµÑéÂ¥ÕÙ¿ªÃ½ÌåÐû²¼»á£¬£¬½éÉÜÆä×îеÄÑо¿Ð§¹û¡ª¡ªngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÑʤ½ÌÊÚÍŶӺ͸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆÒ½ÔºÇ®½½ÌÊÚÍŶÓÔÚ¹ú¼Ê¶¥¼¶Ò½Ñ§ÆÚ¿¯ÃÀ¹úҽѧ»áÔÓÖ¾£¨JAMA£©½ÒÏþÔ´´ÁÙ´²Ñо¿ÂÛÎÄ£¬£¬Ö¤ÊµÁË¡°3¸öÁƳ̵ÄCEV»¯ÁÆ·½°¸Óë¹Å°å6ÁƳ̷½°¸¹ØÓÚ¸ßΣÊÓÍøÄ¤Ä¸Ï¸°ûÁö¾ßÓÐÏàͬµÄÁÆÐ§¡±¡£¡£Ðû²¼»áÓÉngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÖ÷ÈΡ¢¡¢Ò½ÔºÔº³¤¡¢¡¢ÑÛ²¡·ÀÖÎÌìÏÂÖØµãʵÑéÊÒÖ÷ÈÎÁÖºÆÌí½ÌÊÚÖ÷³Ö£¬£¬ÏîÄ¿ÈÏÕæÈË¡¢¡¢ÂÛÎÄ×îºóͨѶ×÷ÕßÑʤ½ÌÊÚ½éÉܸÃÑо¿Ð§¹û¡£¡£

Ñо¿ÍŶÓ
ÊÓÍøÄ¤Ä¸Ï¸°ûÁöÊǶùͯÑÛÄÚ×î³£¼ûµÄ¶ñÐÔÖ×Áö£¬£¬È«ÌìÏÂÿÄêÔ¼ÓÐ8000ÀýÐÂÔö»¼¶ù¡£¡£¾ßÓв¡Àí¸ßΣÒòËØµÄÍíÆÚÊÓÍøÄ¤Ä¸Ï¸°ûÁö»¼¶ùÓнϸߵÄÂÄÚÒÔ¼°Ô¶´¦×ªÒÆ·çÏÕ£¬£¬ÕâÐ©×ªÒÆ³£µ¼Ö²¡ÇéѸËÙ¶ñ»¯£¬£¬ÑÏÖØÍþв»¼¶ùÉúÃü¡£¡£ÏÖÔÚ¹ØÓÚÕâÀ໼¶ùÖ÷ÒªµÄÖÎÁÆ·½°¸ÎªÊõºó¸¨Öú»¯ÁÆ¡£¡£µ«ÓÉÓÚȱ·¦Õë¶Ô¾ßÓв¡Àí¸ßΣÒòËØµÄÍíÆÚÊÓÍøÄ¤Ä¸Ï¸°ûÁö»¼¶ùµÄÁÙ´²Ëæ»úÊÔÑéÊý¾Ý£¬£¬ÏÖÔÚÉÐÎÞ·¨È·¶¨×î¼ÑµÄ»¯ÁÆÁƳ̡£¡£
¹Å°åµÄ6¸öÁƳÌCEV£¨¿¨²¬¡¢¡¢ÒÀÍв´Üպͳ¤´ºÐ¼·½°¸ËäÈ»ÓÐÓ㬣¬µ«ÁƳ̹ý³¤¡¢¡¢²»Á¼·´Ó³¼°²¢·¢Ö¢½Ï¶à£¬£¬¸ø»¼¶ùºÍÆä¼ÒÍ¥´øÀ´¼«Öصļ縺¡£¡£ÎªÁËËõ¶ÌÁƳ̣¬£¬ïÔÌ»¯ÁƸ±×÷Ó㬣¬¼õÇỼ¶ùºÍ¼ÒÍ¥µÄ¼ç¸º£¬£¬Ñʤ½ÌÊÚÍŶӿª´´ÐÔµØÌá³öÁË3¸öÁƳÌCEV»¯ÁÆ·½°¸£¬£¬²¢Ì½Ë÷Á˱¾·½°¸Óë¹Å°å·½°¸ÊÇ·ñ¾ßÓÐÏàͬµÄÓÐÓÃÐÔ¡£¡£
¿ËÈÕ£¬£¬ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÑʤ½ÌÊÚÍŶÓÁªºÏ¸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆÒ½ÔºÇ®½½ÌÊÚÍŶÓÔÚ¹ú¼Ê¶¥¼âҽѧÆÚ¿¯JAMA½ÒÏþÁËÌâΪ¡°Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma £ºA Randomized Clinical Trial¡±µÄÑо¿ÂÛÎÄ¡£¡£ÕâÏîÑо¿ÊÇngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÔÚJAMAÉϵĵڶþƪԴ´ÁÙ´²Ñо¿ÂÛÎÄ£¬£¬Ò²ÊÇÎÒ¹úÑÛ¿ÆÁìÓòÔÚ¸ÃÆÚ¿¯½ÒÏþµÄµÚ¶þƪÁÙ´²Ñо¿ÂÛÖø¡£¡£
±¾Ñо¿»Ø¸²Á˸ßΣÊÓÍøÄ¤Ä¸Ï¸°ûÁö»¼¶ùÊõºó¸¨Öú»¯ÁƵÄ×î¼ÑÁƳÌÎÊÌ⣬£¬Ñо¿Ð§¹ûÅú×¢£¬£¬3¸öÁƳ̵ÄCEV»¯ÁÆ·½°¸Óë¹Å°å·½°¸¾ßÓÐÏàͬµÄÁÆÐ§£¬£¬ÕâÓÐÍûʹ¸ü¶à¸ßΣÊÓÍøÄ¤Ä¸Ï¸°ûÁö»¼¶ùÊÜÒæ²¢Ð´ÈëÖ¸ÄÏ¡£¡£
ÕâÏîǰհÐÔ¡¢¡¢·ÇÁÓÐ§Ëæ»ú±ÈÕÕÁÙ´²Ñо¿ÄÉÈëÁË187Àý½ÓÊÜÑÛÇòÕª³ýÊõÇÒ¾ßÓв¡Àí¸ßΣÒòËØµÄµ¥ÑÛÊÓÍøÄ¤Ä¸Ï¸°ûÁö»¼¶ù¡£¡£»£»£»¼¶ùËæ»ú·ÖΪÁ½×飬£¬»®·Ö½ÓÊÜ3¸öÁƳ̻ò6¸öÁƳ̵ÄCEV»¯ÁÆ¡£¡£Ñо¿µÄÖ÷Ҫϳ¡Ö¸±êΪÎÞ²¡ÉúÑÄÂÊ£¨DFS£©£¬£¬´ÎҪϳ¡Ö¸±êΪ×ÜÉúÑÄÂÊ¡¢¡¢Çå¾²ÐÔ¡¢¡¢¾¼Ã¸ºµ£¡£¡£¡¢¡¢»¼¶ùÉúÑÄÖÊÁ¿µÈ¡£¡£
Ñо¿Ð§¹ûÏÔʾ£¬£¬ÔÚÖ÷Ҫϳ¡Ö¸±ê£¨5ÄêÎÞ²¡ÉúÑÄÂÊ£©·½Ã棬£¬3ÁƳÌ×éºÍ6ÁƳÌ×é»®·ÖΪ90.4%ºÍ89.2%£¬£¬ÎÞÏÔÖø²î±ð¡£¡£±ðµÄ£¬£¬ÔÚ5Äê×ÜÉúÑÄÂÊ·½Ã棬£¬Á½×éÒ²ÎÞͳ¼ÆÑ§²î±ð£¨91.5% VS 89.3%£©¡£¡£


3ÁƳÌ×é±ÈÕչŰå6ÁƳÌ×飬£¬ÎÞ²¡ÉúÑÄÂÊÎÞÏÔÖø²î±ð
ÔÚÖÎÁÆÇå¾²ÐÔ·½Ã棬£¬3ÁƳÌ×éÓÐ79Ãû£¨80.6%£©»¼¶ùÂÄÀúÁ˹²282´Î²»Á¼ÊÂÎñ¡£¡£¶øÔÚ6ÁƳÌ×éÖУ¬£¬89Ãû»¼¶ù£¨95.7%£©ÂÄÀúÁË×ܼÆ681´Î²»Á¼ÊÂÎñ¡£¡£±ðµÄ£¬£¬ÔÚ¾¼Ã¼ç¸º·½Ã棬£¬3ÁƳÌ×é±È6ÁƳÌ×éÖ±½Ó±¾Ç®ºÍ¼ä½Ó±¾Ç®¸üµÍ¡£¡£
±¾Ñо¿Ö¤Êµ£¬£¬3¸öÁƳÌCEV»¯ÁÆÔÚÔ¤·À×ªÒÆºÍ½µµÍéæÃüÂÊ·½ÃæÓë6¸öÁƳÌͬÑùÓÐÓ㬣¬ÇÒ¸±×÷ÓøüÉÙ£¬£¬±¾Ç®¸üµÍ¡£¡£
Õâ¿ÉÄܳÉΪ¡°¾ßÓиßΣ²¡ÀíÌØÕ÷µÄÊÓÍøÄ¤Ä¸Ï¸°ûÁö¡±µÄÖÎÁÆÐ±ê×¼£¬£¬ÓÐÍûʹ¸ü¶à»¼¶ùÊÜÒæ£¬£¬²¢¿ÉÄܱ»Ð´Èë¹ú¼ÊÖ¸ÄÏ¡£¡£
JAMAÆÚ¿¯¶Ô±¾Ñо¿¸øÓèÁË¸ß¶ÈÆÀ¼Û£¬£¬ÒÔΪÕâÏîÑо¿¶ÔÓÐÊýÖ×ÁöÖÎÁƾßÓÐÖØ´óÒâÒå¡£¡£¹ú¼Ê¶¥¼¶ÑÛÖ×Áöר¼ÒCarol Lally Shields½ÌÊÚ̸Â۳ƣ¬£¬¸ÃÑо¿µÄ3¸öÁƳÌCEV»¯ÁÆ·½°¸ÊÇÀï³Ì±®Ê½µÄ£¬£¬ÓÉÓÚËü¼ÈÕü¾ÈÁËÉúÃü£¬£¬ÓÖ¼õÇáÁË»¼Õߵľ¼ÃѹÁ¦£¬£¬Ìá¸ßÁËÖÎÁÆÍê³ÉÂÊ¡£¡£
ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄ¡¢¡¢ÑÛ²¡·ÀÖÎÌìÏÂÖØµãʵÑéÊÒΪ±¾Ñо¿µÚÒ»×÷Õßµ¥Î»ºÍ×îºóͨѶ×÷Õßµ¥Î»¡£¡£ÖÐɽÑÛ¿ÆÖÐÐÄÑʤ½ÌÊں͸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆÒ½ÔºÇ®½½ÌÊÚΪÅäºÏͨѶ×÷Õߣ¬£¬ÖÐɽÑÛ¿ÆÖÐÐĸ±Ö÷ÈÎҽʦҶ»Ûݼ¡¢¡¢¸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆÒ½Ôº¸±Ö÷ÈÎҽʦѦ¿µÎªÅäºÏµÚÒ»×÷Õß¡£¡£
ÂÛÎÄÁ´½Ó£º
https://jamanetwork.com/journals/jama/article-abstract/2825162